Hugo™ RAS system in the field of surgical oncology: feasibility, safety, and early oncological outcomes

BACKGROUND: The Hugo™ Robotic-Assisted Surgery (RAS) System is a novel modular robotic platform with expanding applications in the field of surgical oncology. This study evaluated its feasibility, perioperative safety, and early oncological outcomes during initial adoption in a tertiary care centre. METHODS: A retrospective analysis of 75 consecutive patients who underwent robotic-assisted oncological surgery using the Hugo™ RAS System between June 2025 and May 2026 was undertaken. Demographic characteristics, operative parameters, perioperative outcomes, and early oncological results were assessed. RESULTS: Procedures were performed across thoracic (nt=13), abdominal (na=25), and pelvic (np=37) subsites. Mean console time was 298 minutes, and mean estimated blood loss was 192 ml. The overall conversion rate was 6.7% (5/75), including one conversion to thoracoscopic surgery and four conversions to open utility incision with none attributable to robotic system malfunction. The overall complication rate was 10.6%, with major complications occurring in 1.3% of patients. Mean length of hospital stay was 5 days. The 30-day and 90 day readmission rate was 4%. No perioperative or 30-day mortality was observed. While 90-day mortality was 1.3% (1/75). R0 resection was achieved in all patients. Lymph node yields were oncologically adequate across thoracic, abdominal, and pelvic subsites, with mean yields of 18.8 nodes following esophagectomy, 33 nodes for gastric resections, 20.5 nodes for colectomies, and 17.5 nodes for rectal resections, consistent with accepted oncological standards. CONCLUSIONS: The Hugo™ RAS System is a feasible and safe platform for a wide spectrum of oncological procedures across thoracic, abdominal, and pelvic subsites. Early outcomes demonstrate acceptable perioperative morbidity and promising oncological adequacy. With appropriate training and case selection, the Hugo™ RAS system has the potential to expand the adoption of robotic surgery, particularly in resource-constrained settings.

Authors

Institutions

Publication Details

Journal
Updates in Surgery
Published
2026-11-20
DOI
https://doi.org/10.1007/s13304-026-02932-z
Primary Topic
Minimally Invasive Surgical Techniques
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Hugo™ RAS system in the field of surgical oncology: feasibility, safety, and early oncological outcomes

Preethi S. Shetty, Akhil Palod, Naveena A. N. Kumar, Ananthakrishnan Balakrishnan et al.
4 links
Updates in Surgery
Minimally Invasive Surgical Techniques
article

Hugo™ RAS system in the field of surgical oncology: feasibility, safety, and early oncological outcomes

Preethi S. Shetty, Akhil Palod, Naveena A. N. Kumar, Ananthakrishnan Balakrishnan, Neethu Tomy, Varun TN, Vidyashankar CJ, Nawaz Usman, Nischitha Jayarama
article en

Abstract

BACKGROUND: The Hugo™ Robotic-Assisted Surgery (RAS) System is a novel modular robotic platform with expanding applications in the field of surgical oncology. This study evaluated its feasibility, perioperative safety, and early oncological outcomes during initial adoption in a tertiary care centre. METHODS: A retrospective analysis of 75 consecutive patients who underwent robotic-assisted oncological surgery using the Hugo™ RAS System between June 2025 and May 2026 was undertaken. Demographic characteristics, operative parameters, perioperative outcomes, and early oncological results were assessed. RESULTS: Procedures were performed across thoracic (nt=13), abdominal (na=25), and pelvic (np=37) subsites. Mean console time was 298 minutes, and mean estimated blood loss was 192 ml. The overall conversion rate was 6.7% (5/75), including one conversion to thoracoscopic surgery and four conversions to open utility incision with none attributable to robotic system malfunction. The overall complication rate was 10.6%, with major complications occurring in 1.3% of patients. Mean length of hospital stay was 5 days. The 30-day and 90 day readmission rate was 4%. No perioperative or 30-day mortality was observed. While 90-day mortality was 1.3% (1/75). R0 resection was achieved in all patients. Lymph node yields were oncologically adequate across thoracic, abdominal, and pelvic subsites, with mean yields of 18.8 nodes following esophagectomy, 33 nodes for gastric resections, 20.5 nodes for colectomies, and 17.5 nodes for rectal resections, consistent with accepted oncological standards. CONCLUSIONS: The Hugo™ RAS System is a feasible and safe platform for a wide spectrum of oncological procedures across thoracic, abdominal, and pelvic subsites. Early outcomes demonstrate acceptable perioperative morbidity and promising oncological adequacy. With appropriate training and case selection, the Hugo™ RAS system has the potential to expand the adoption of robotic surgery, particularly in resource-constrained settings.

Updates in Surgery
Manipal Academy of Higher Education (IN), Kasturba Medical College Hospital (IN), Kasturba Medical College, Manipal (IN)
Good health and well-being
Minimally Invasive Surgical Techniques
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon